Cargando…

CDK7 inhibitors as anticancer drugs

Cyclin-dependent kinase 7 (CDK7), along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs progression through the cell cycle via T-loop phosphorylation of cell cycle CDKs. CAK is also a component of the general transcription factor, TFIIH. CDK7-mediated phosphorylation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sava, Georgina P., Fan, Hailing, Coombes, R. Charles, Buluwela, Lakjaya, Ali, Simak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497306/ https://www.ncbi.nlm.nih.gov/pubmed/32385714 http://dx.doi.org/10.1007/s10555-020-09885-8

Ejemplares similares

ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
por: Sava, Georgina P., et al.
Publicado: (2019)

Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK directed activation of NF-κB
por: Periyasamy, Manikandan, et al.
Publicado: (2021)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
por: Coombes, R. C., et al.
Publicado: (2023)

ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases
por: Lopez-Garcia, Jorge, et al.
Publicado: (2006)

The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation
por: Smith, Linda, et al.
Publicado: (2017)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Author Correction: The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation
por: Smith, Linda, et al.
Publicado: (2018)

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
por: Constantin, Theodora A., et al.
Publicado: (2023)

Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors
por: Al-Warhi, Tarfah, et al.
Publicado: (2020)

Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma
por: Hu, Qinchao, et al.
Publicado: (2020)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
por: Coombes, R. C., et al.
Publicado: (2023)

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
por: Harrod, Alison, et al.
Publicado: (2022)

Engineered repressors are potent inhibitors of androgen receptor activity
por: Brooke, Greg N., et al.
Publicado: (2014)

Targeting CDK4/6 for Anticancer Therapy
por: Qi, Jiating, et al.
Publicado: (2022)

Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation
por: Ma, Xinqi, et al.
Publicado: (2018)

Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
por: Castellví, Marc, et al.
Publicado: (2020)

2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942
por: Greber, Basil J., et al.
Publicado: (2021)

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
por: Kwiatkowski, Nicholas, et al.
Publicado: (2014)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
por: Yuan, Kai, et al.
Publicado: (2021)

miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts
por: Pellegrino, Loredana, et al.
Publicado: (2013)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif
por: Lucey, Marie J., et al.
Publicado: (2005)

Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
por: Choi, Yun Jung, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
por: Chen, Elijah W., et al.
Publicado: (2019)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Cyclin E1-CDK 2, a potential anticancer target
por: Fang, Dongdong, et al.
Publicado: (2016)

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
por: Natoni, Alessandro, et al.
Publicado: (2013)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations
por: Kumar, Vikas, et al.
Publicado: (2021)

Quantifying CDK inhibitor selectivity in live cells
por: Wells, Carrow I., et al.
Publicado: (2020)

Identification and Characterization of an Irreversible Inhibitor of CDK2
por: Anscombe, Elizabeth, et al.
Publicado: (2015)

2D-QSAR and docking study of a series of coumarin derivatives as inhibitors of CDK (anticancer activity) with an application of the molecular docking method
por: Kasmi, Rania, et al.
Publicado: (2020)

Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies
por: Hashem, Heba E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ln6gaq2b2b50iavtd7n00bdpqs